Physician profile
Thomas Mckinley
NPI 1639250830
$881.70
in general payments reported to CMS, 2019-2025
17 companies · $51.27 in 2025
The $51.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.75 · 2020: $13.00 · 2022: $193 · 2023: $309 · 2024: $275 · 2025: $51.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.95 | 2022-2024 | |
| Amgen INC. | $112.59 | 2022-2024 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $104.94 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $92.09 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $87.13 | 2022-2025 | |
| Smith+Nephew, INC. | $85.07 | 2022-2024 | Collagenase Santyl, Regranex |
| Novartis Pharmaceuticals Corporation | $54.11 | 2023-2025 | |
| Lilly USA, LLC | $39.49 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.91 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $26.16 | 2023-2024 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $16.61 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $16.24 | 2024 | Voquezna |
| Abbott Laboratories | $15.56 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $15.42 | 2019 | |
| Melinta Therapeutics, LLC | $14.24 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.33 | 2019 | |
| Kerecis Limited | $11.86 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mckinley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.